AVEO to Present at the 28th Annual Piper Jaffray Healthcare Conference
November 22 2016 - 7:00AM
Business Wire
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey,
president and chief executive officer, will present at the 28th
Annual Piper Jaffray Healthcare Conference on Wednesday, November
30, 2016 at 3:30 PM Eastern Time. The conference is being held at
the New York Palace Hotel.
A live webcast can be accessed by visiting the investors section
of the Company’s website at www.aveooncology.com. A replay of the
webcast will be archived for 30 days following the presentation
date.
About AVEO
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to
advancing a broad portfolio of targeted therapeutics for oncology
and other areas of unmet medical need. The company is focused on
developing and commercializing its lead candidate tivozanib, a
potent, selective, long half-life inhibitor of vascular endothelial
growth factor 1, 2 and 3 receptors, in North America as a treatment
for Renal Cell Carcinoma and other cancers. AVEO is leveraging
multiple partnerships to develop and commercialize tivozanib in
non-oncologic indications worldwide and oncology indications
outside of North America, as well as to progress its pipeline of
novel therapeutic candidates in cancer and cachexia (wasting
syndrome). For more information, please visit the company’s website
at www.aveooncology.com.
AVEO Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements of AVEO
that involve substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Actual results or events
could differ materially due to a number of important factors,
including risks discussed in the section titled “Risk Factors” in
AVEO’s most recent Annual Report on Form 10-K, its quarterly
reports on Form 10-Q and its other filings with the SEC. The
forward-looking statements in this press release represent AVEO’s
views as of the date of this press release. AVEO anticipates that
subsequent events and developments may cause its views to change.
While AVEO may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. You should, therefore, not rely on these forward-looking
statements as representing AVEO’s views as of any date other than
the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161122005123/en/
Argot PartnersDavid Pitts,
212-600-1902aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Aug 2024 to Sep 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Sep 2023 to Sep 2024